CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: biodistribution</title> <meta name="description" content="Search results for: biodistribution"> <meta name="keywords" content="biodistribution"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="biodistribution" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="biodistribution"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 43</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: biodistribution</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">43</span> Time Dependent Biodistribution Modeling of 177Lu-DOTATOC Using Compartmental Analysis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20Mousavi-Daramoroudi">M. Mousavi-Daramoroudi</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia"> H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=F.%20Abbasi-Davani"> F. Abbasi-Davani</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri"> S. Zolghadri</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In this study, <sup>177</sup>Lu-DOTATOC was prepared under optimized conditions (radiochemical purity: > 99%, radionuclidic purity: > 99%). The percentage of injected dose per gram (%ID/g) was calculated for organs up to 168 h post injection. Compartmental model was applied to mathematical description of the drug behaviour in tissue at different times. The biodistribution data showed the significant excretion of the radioactivity from the kidneys. The adrenal and pancreas, as major expression sites for somatostatin receptor (SSTR), had significant uptake. A pharmacokinetic model of <sup>177</sup>Lu-DOTATOC was presented by compartmental analysis which demonstrates the behavior of the complex. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=biodistribution" title="biodistribution">biodistribution</a>, <a href="https://publications.waset.org/abstracts/search?q=compartmental%20modeling" title=" compartmental modeling"> compartmental modeling</a>, <a href="https://publications.waset.org/abstracts/search?q=%C2%B9%E2%81%B7%E2%81%B7Lu" title=" ¹⁷⁷Lu"> ¹⁷⁷Lu</a>, <a href="https://publications.waset.org/abstracts/search?q=Octreotide" title=" Octreotide"> Octreotide</a> </p> <a href="https://publications.waset.org/abstracts/93824/time-dependent-biodistribution-modeling-of-177lu-dotatoc-using-compartmental-analysis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/93824.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">220</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">42</span> Production, Quality Control, and Biodistribution Assessment of 111In-BPAMD as a New Bone Imaging Agent</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia">H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Aghanejad"> A. Aghanejad</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Mirzaei"> A. Mirzaei</a>, <a href="https://publications.waset.org/abstracts/search?q=R.%20Enayati"> R. Enayati</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20R.%20Jalilian"> A. R. Jalilian</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri"> S. Zolghadri</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Bone metastases occur in many cases at an early stage of the tumour disease; however, their symptoms are recognized rather late. The aim of this study was the preparation and quality control of 111In-BPAMD for diagnostic purposes. 111In was produced at the Agricultural, Medical, and Industrial Research School (AMIRS) by means of 30 MeV cyclotron via natCd(p,x)111In reaction. Complexion of In‐111 with BPAMD was carried out by using acidic solution of 111InCl3 and BPAMD in absolute water. The effect of various parameters such as temperature, ligand concentration, pH, and time on the radiolabeled yield was studied. 111In-BPAMD was prepared successfully with the radiochemical purity of 95% at the optimized condition (100 µg of BPAMD, pH=5, and at 90°C for 1 h) which was measured by ITLC method. The final solution was injected to wild-type mice and biodistribution was determined up to 72 h. SPECT images were acquired after 2 and 24 h post injection. Both the biodistribution studies and SPECT imaging indicated high bone uptake while accumulation in other organs was approximately negligible. The results show that 111In-BPAMD can be used as an excellent tracer for diagnosis of bone metastases by SPECT imaging. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=biodistribution" title="biodistribution">biodistribution</a>, <a href="https://publications.waset.org/abstracts/search?q=BPAMD" title=" BPAMD"> BPAMD</a>, <a href="https://publications.waset.org/abstracts/search?q=111In" title=" 111In"> 111In</a>, <a href="https://publications.waset.org/abstracts/search?q=SPECT" title=" SPECT"> SPECT</a> </p> <a href="https://publications.waset.org/abstracts/18062/production-quality-control-and-biodistribution-assessment-of-111in-bpamd-as-a-new-bone-imaging-agent" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/18062.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">561</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">41</span> Biodistribution Study of 68GA-PDTMP as a New Bone Pet Imaging Agent</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=N.%20Tadayon">N. Tadayon</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia"> H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri"> S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Ramazani"> A. Ramazani</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20R.%20Jalilian"> A. R. Jalilian</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In this study, 68Ga-PDTMP was prepared as a new agent for bone imaging. 68Ga was obtained from SnO2 based generator. A certain volume of the PDTMP solution was added to the vial containing 68GaCl3 and the pH of the mixture was adjusted to 4 using HEPES. Radiochemical purity of the radiolabelled complex was checked by thin layer chromatography. Biodistribution of this new agent was assessed in rats after intravenously injection of the complex. For this purpose, the rats were killed at specified times after injection and the weight and activity of each organ was measured. Injected dose per gram was calculated by dividing the activity of each organ to the total injected activity and the mass of each organ. As expected the most of the activity was accumulated in the bone tissue. The radiolabelled compound was extracted from blood very fast. This new bone-seeking complex can be considered as a good candidate of PET-based radiopharmaceutical for imaging of bone metastases. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=biodistribution" title="biodistribution">biodistribution</a>, <a href="https://publications.waset.org/abstracts/search?q=Ga-68" title=" Ga-68"> Ga-68</a>, <a href="https://publications.waset.org/abstracts/search?q=imaging" title=" imaging"> imaging</a>, <a href="https://publications.waset.org/abstracts/search?q=PDTMP" title=" PDTMP"> PDTMP</a> </p> <a href="https://publications.waset.org/abstracts/38752/biodistribution-study-of-68ga-pdtmp-as-a-new-bone-pet-imaging-agent" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/38752.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">358</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">40</span> Modeling the Time Dependent Biodistribution of a 177Lu Labeled Somatostatin Analogues for Targeted Radiotherapy of Neuroendocrine Tumors Using Compartmental Analysis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mahdieh%20Jajroudi">Mahdieh Jajroudi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Developing a pharmacokinetic model for the neuroendocrine tumors therapy agent 177Lu-DOTATATE in nude mice bearing AR42J rat pancreatic tumor to investigate and evaluate the behavior of the complex was the main purpose of this study. The utilization of compartmental analysis permits the mathematical differencing of tissues and organs to become acquainted with the concentration of activity in each fraction of interest. Biodistribution studies are onerous and troublesome to perform in humans, but such data can be obtained facilely in rodents. A physiologically based pharmacokinetic model for scaling up activity concentration in particular organs versus time was developed. The mathematical model exerts physiological parameters including organ volumes, blood flow rates, and vascular permabilities; the compartments (organs) are connected anatomically. This allows the use of scale-up techniques to forecast new complex distribution in humans' each organ. The concentration of the radiopharmaceutical in various organs was measured at different times. The temporal behavior of biodistribution of 177Lu labeled somatostatin analogues was modeled and drawn as function of time. Conclusion: The variation of pharmaceutical concentration in all organs is characterized with summation of six to nine exponential terms and it approximates our experimental data with precision better than 1%. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=biodistribution%20modeling" title="biodistribution modeling">biodistribution modeling</a>, <a href="https://publications.waset.org/abstracts/search?q=compartmental%20analysis" title=" compartmental analysis"> compartmental analysis</a>, <a href="https://publications.waset.org/abstracts/search?q=177Lu%20labeled%20somatostatin%20analogues" title=" 177Lu labeled somatostatin analogues"> 177Lu labeled somatostatin analogues</a>, <a href="https://publications.waset.org/abstracts/search?q=neuroendocrine%20tumors" title=" neuroendocrine tumors"> neuroendocrine tumors</a> </p> <a href="https://publications.waset.org/abstracts/32538/modeling-the-time-dependent-biodistribution-of-a-177lu-labeled-somatostatin-analogues-for-targeted-radiotherapy-of-neuroendocrine-tumors-using-compartmental-analysis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/32538.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">368</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">39</span> Comparative Study between the Absorbed Dose of 67ga-Ecc and 68ga-Ecc</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia">H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri"> S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Shanesazzadeh"> S. Shanesazzadeh</a>, <a href="https://publications.waset.org/abstracts/search?q=A.Lahooti"> A.Lahooti</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20R.%20Jalilian"> A. R. Jalilian</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In this study, 68Ga-ECC and 67Ga-ECC were both prepared with the radiochemical purity of higher than 97% in less than 30 min. The biodistribution data for 68Ga-ECC showed the extraction of the most of the activity from the urinary tract. The absorbed dose was estimated based on biodistribution data in mice by the medical internal radiation dose (MIRD) method. Comparison between human absorbed dose estimation for these two agents indicated the values of approximately ten-fold higher after injection of 67Ga-ECC than 68Ga-ECC in the most organs. The results showed that 68Ga-ECC can be considered as a more potential agent for renal imaging compared to 67Ga-ECC. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=effective%20absorbed%20dose" title="effective absorbed dose">effective absorbed dose</a>, <a href="https://publications.waset.org/abstracts/search?q=ethylenecysteamine%20cysteine" title=" ethylenecysteamine cysteine"> ethylenecysteamine cysteine</a>, <a href="https://publications.waset.org/abstracts/search?q=Ga-67" title=" Ga-67"> Ga-67</a>, <a href="https://publications.waset.org/abstracts/search?q=Ga-68" title=" Ga-68"> Ga-68</a> </p> <a href="https://publications.waset.org/abstracts/32476/comparative-study-between-the-absorbed-dose-of-67ga-ecc-and-68ga-ecc" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/32476.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">469</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">38</span> Development of 90y-Chitosan Complex for Radiosynovectomy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=A.%20Mirzaei">A. Mirzaei</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri"> S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Athari-Allaf"> M. Athari-Allaf</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia"> H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20R.%20Jalilian"> A. R. Jalilian</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Rheumatoid arthritis is the most common autoimmune disease, leading to the destruction of the joints. The aim of this study was the preparation of 90Y-chitosan complex as a novel agent for radiosynovectomy. The complex was prepared in the diluted acetic acid solution. At the optimized condition, the radiochemical purity of higher than 99% was obtained by ITLC method on Whatman No. 1 and by using a mixture of methanol/water/acetic acid (4:4:2) as the mobile phase. The complex was stable in acidic media (pH=3) and its radiochemical purity was above 98% even after 48 hours. The biodistribution data in rats showed that there was no significant leakage of the injected activity even after 48 h. Considering all of the excellent features of the complex, 90Y-chitosan can be used to manipulate synovial inflammation effectively. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chitosan" title="chitosan">chitosan</a>, <a href="https://publications.waset.org/abstracts/search?q=Y-90" title=" Y-90"> Y-90</a>, <a href="https://publications.waset.org/abstracts/search?q=radiosynovectomy" title=" radiosynovectomy"> radiosynovectomy</a>, <a href="https://publications.waset.org/abstracts/search?q=biodistribution" title=" biodistribution"> biodistribution</a> </p> <a href="https://publications.waset.org/abstracts/23149/development-of-90y-chitosan-complex-for-radiosynovectomy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/23149.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">483</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">37</span> Estimation of Human Absorbed Dose Using Compartmental Model</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20Mousavi-Daramoroudi">M. Mousavi-Daramoroudi</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia"> H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=F.%20Abbasi-Davani"> F. Abbasi-Davani</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri"> S. Zolghadri</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Dosimetry is an indispensable and precious factor in patient treatment planning to minimize the absorbed dose in vital tissues. In this study, compartmental model was used in order to estimate the human absorbed dose of <sup>177</sup>Lu-DOTATOC from the biodistribution data in wild type rats. For this purpose, <sup>177</sup>Lu-DOTATOC was prepared under optimized conditions and its biodistribution was studied in male Syrian rats up to 168 h. Compartmental model was applied to mathematical description of the drug behaviour in tissue at different times. Dosimetric estimation of the complex was performed using radiation absorbed dose assessment resource (RADAR). The biodistribution data showed high accumulation in the adrenal and pancreas as the major expression sites for somatostatin receptor (SSTR). While kidneys as the major route of excretion receive 0.037 mSv/MBq, pancreas and adrenal also obtain 0.039 and 0.028 mSv/MBq. Due to the usage of this method, the points of accumulated activity data were enhanced, and further information of tissues uptake was collected that it will be followed by high (or improved) precision in dosimetric calculations. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=compartmental%20modeling" title="compartmental modeling">compartmental modeling</a>, <a href="https://publications.waset.org/abstracts/search?q=human%20absorbed%20dose" title=" human absorbed dose"> human absorbed dose</a>, <a href="https://publications.waset.org/abstracts/search?q=%C2%B9%E2%81%B7%E2%81%B7Lu-DOTATOC" title=" ¹⁷⁷Lu-DOTATOC"> ¹⁷⁷Lu-DOTATOC</a>, <a href="https://publications.waset.org/abstracts/search?q=Syrian%20rats" title=" Syrian rats"> Syrian rats</a> </p> <a href="https://publications.waset.org/abstracts/94409/estimation-of-human-absorbed-dose-using-compartmental-model" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/94409.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">193</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">36</span> Biodistribution Studies of 177Lu-DOTATOC in Mouse Tumor Model: Possible Utilization in Adenocarcinoma Breast Cancer Treatment</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20Mousavi-Daramoroudi">M. Mousavi-Daramoroudi</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia"> H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=F.%20Abbasi-Davani"> F. Abbasi-Davani</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri"> S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Kakaei"> S. Kakaei</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Despite the appropriate characteristics of <sup>177</sup>Lu and DOTATOC, to our best knowledge, the therapeutic benefit of <sup>177</sup>Lu-DOTATOC complex in breast cancer has not been reported until now. In this study, biodistribution of <sup>177</sup>Lu-DOTA-TOC in mouse tumor model for evaluation of possible utilization of this complex in breast cancer treatment was investigated.<sup>177</sup>Lu was prepared with the specific activity of 2.6-3 GBq.mg<sup>-1</sup> and radionuclidic purity higher than 99%. The radiolabeled complex was prepared in the optimized conditions with the radiochemical purity higher than 99%. The final solution was injected to the BALB/c mice with adenocarcinoma breast cancer. The biodistribution results showed major accumulation in the kidneys as the major excretion route and the somatostatin receptor-positive tissues such as pancreas compared with the other tissues. Also, significant uptake was observed in tumor even in longer time after injection. According to the results obtained in this research study, somatostatin receptors expressed in breast cancers can be targeted with DOTATOC analogues especially with <sup>177</sup>Lu-DOTATOC as an ideal therapeutic agent. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=%C2%B9%E2%81%B7%E2%81%B7Lu" title="¹⁷⁷Lu">¹⁷⁷Lu</a>, <a href="https://publications.waset.org/abstracts/search?q=adenocarcinoma%20breast%20cancer" title=" adenocarcinoma breast cancer"> adenocarcinoma breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=DOTATOC" title=" DOTATOC"> DOTATOC</a>, <a href="https://publications.waset.org/abstracts/search?q=BALB%2Fc%20mice" title=" BALB/c mice"> BALB/c mice</a> </p> <a href="https://publications.waset.org/abstracts/80226/biodistribution-studies-of-177lu-dotatoc-in-mouse-tumor-model-possible-utilization-in-adenocarcinoma-breast-cancer-treatment" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/80226.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">227</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">35</span> Absorbed Dose Estimation of 68Ga-EDTMP in Human Organs </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri">S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia"> H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20R.%20Jalilian"> A. R. Jalilian</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Bone metastases are observed in a wide range of cancers leading to intolerable pain. While early detection can help the physicians in the decision of the type of treatment, various radiopharmaceuticals using phosphonates like <sup>68</sup>Ga-EDTMP have been developed. In this work, due to the importance of absorbed dose, human absorbed dose of this new agent was calculated for the first time based on biodistribution data in Wild-type rats. <sup>68</sup>Ga was obtained from <sup>68</sup>Ge/<sup>68</sup>Ga generator with radionuclidic purity and radiochemical purity of higher than 99%. The radiolabeled complex was prepared in the optimized conditions. Radiochemical purity of the radiolabeled complex was checked by instant thin layer chromatography (ITLC) method using Whatman No. 2 paper and saline. The results indicated the radiochemical purity of higher than 99%. The radiolabelled complex was injected into the Wild-type rats and its biodistribution was studied up to 120 min. As expected, major accumulation was observed in the bone. Absorbed dose of each human organ was calculated based on biodistribution in the rats using RADAR method. Bone surface and bone marrow with 0.112 and 0.053 mSv/MBq, respectively, received the highest absorbed dose. According to these results, the radiolabeled complex is a suitable and safe option for PET bone imaging. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=absorbed%20dose" title="absorbed dose">absorbed dose</a>, <a href="https://publications.waset.org/abstracts/search?q=EDTMP" title=" EDTMP"> EDTMP</a>, <a href="https://publications.waset.org/abstracts/search?q=%E2%81%B6%E2%81%B8Ga" title=" ⁶⁸Ga"> ⁶⁸Ga</a>, <a href="https://publications.waset.org/abstracts/search?q=rats" title=" rats"> rats</a> </p> <a href="https://publications.waset.org/abstracts/81329/absorbed-dose-estimation-of-68ga-edtmp-in-human-organs" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/81329.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">194</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">34</span> Development of 111In-DOTMP as a New Bone Imaging Agent</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia">H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri"> S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=AR.%20Jalilian"> AR. Jalilian</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Mirzaei"> A. Mirzaei</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Bahrami-Samani"> A. Bahrami-Samani</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Erfani"> M. Erfani</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The objective of this study is the preparation of 111In-DOTMP as a new bone imaging agent. 111In was produced at the Agricultural, Medical and Industrial Research School (AMIRS) by means of 30 MeV cyclotron via natCd(p,x)111In reaction. Complexion of In‐111 with DOTMP was carried out by adding 0.1 ml of the stock solution (50 mg/ml in 2 N NaoH) to the vial containing 1 mCi of 111In. pH of the mixture was adjusted to 7-8 by means of phosphate buffer. The radiochemical purity of the complex at the optimized condition was higher than 98% (by using whatman No.1 paper in NH4OH:MeOH: H2O (0.2:2:4)). Both the biodistribution studies and SPECT imaging indicated high bone uptake. The ratio of bone to other soft tissue accumulation was significantly high which permit to observe high quality images. The results show that 111In-DOTMP can be used as a suitable tracer for diagnosis of bone metastases by SPECT imaging. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=biodistribution" title="biodistribution">biodistribution</a>, <a href="https://publications.waset.org/abstracts/search?q=DOTMP" title=" DOTMP"> DOTMP</a>, <a href="https://publications.waset.org/abstracts/search?q=111In" title=" 111In"> 111In</a>, <a href="https://publications.waset.org/abstracts/search?q=SPECT" title=" SPECT"> SPECT</a> </p> <a href="https://publications.waset.org/abstracts/17000/development-of-111in-dotmp-as-a-new-bone-imaging-agent" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/17000.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">534</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">33</span> Human Absorbed Dose Assessment of 68Ga-Dotatoc Based on Biodistribution Data in Syrian Rats</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri">S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Naderi"> M. Naderi</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia"> H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Ramazani"> A. Ramazani</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20R.%20Jalilian"> A. R. Jalilian</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The aim of this work was to evaluate the values of absorbed dose of 68Ga-DOTATOC in numerous human organs. 68Ga-DOTATOC was prepared with the radiochemical purity of higher than 98% and by specific activity of 39.6 MBq/nmol. The complex demonstrated great stability at room temperature and in human serum at 37° C at least 2 h after preparation. Significant uptake was observed in somatostatin receptor-positive tissues such as pancreas and adrenal. The absorbed dose received by human organs was evaluated based on biodistribution studies in Syrian rats by the radiation absorbed dose assessment resource (RADAR) method. Maximum absorbed dose was obtained in the pancreas, kidneys, and adrenal with 0.105, 0.074, and 0.010 mGy/MBq, respectively. The effective absorbed dose was 0.026 mSv/MBq for 68Ga-DOTATOC. The results showed that 68Ga-DOTATOC can be considered as a safe and effective agent for clinically PET imaging applications. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=effective%20absorbed%20dose" title="effective absorbed dose">effective absorbed dose</a>, <a href="https://publications.waset.org/abstracts/search?q=Ga-68" title=" Ga-68"> Ga-68</a>, <a href="https://publications.waset.org/abstracts/search?q=octreotide" title=" octreotide"> octreotide</a>, <a href="https://publications.waset.org/abstracts/search?q=MIRD" title=" MIRD"> MIRD</a> </p> <a href="https://publications.waset.org/abstracts/32477/human-absorbed-dose-assessment-of-68ga-dotatoc-based-on-biodistribution-data-in-syrian-rats" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/32477.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">526</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">32</span> Novel Liposomal Nanocarriers For Long-term Tumor Imaging</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohamad%20Ahrari">Mohamad Ahrari</a>, <a href="https://publications.waset.org/abstracts/search?q=Kayvan%20Sadri"> Kayvan Sadri</a>, <a href="https://publications.waset.org/abstracts/search?q=Mahmoud%20Reza%20Jafari"> Mahmoud Reza Jafari</a> </p> <p class="card-text"><strong>Abstract:</strong></p> PEGylated liposomes have a smaller volume of distribution and decreased clearance, consequently, due to their more prolonged presence in bloodstream and maintaining their stability during this period, these liposomes can be applied for imaging tumoral sites. The purpose of this study is to develop an appropriate radiopharmaceutical agent in long-term imaging for improved diagnosis and evaluation of tumors. In this study, liposomal formulations encapsulating albumin is synthesized by solvent evaporation method along with homogenization, and their characteristics were assessed. Then these liposomes labeled by Philips method and the rate of stability of labeled liposomes in serum, and ultimately the rate of biodistribution and gamma scintigraphy in C26-colon carcinoma tumor-bearing mice, were studied. The result of the study of liposomal characteristics displayed that capable of accumulating in tumor sites based of EPR phenomenon. these liposomes also have high stability for maintaining encapsulated albumin in a long time. In the study of biodistribution of these liposomes in mice, they accumulated more in the kidney, liver, spleen, and tumor sites, which, even after clearing formulations in the bloodstream, they existed in high levels in these organs up to 96 hours. In gamma scintigraphy also, organs with high activity accumulation from early hours up to 96 hours were visible in the form of hot spots. concluded that PEGylated liposomal formulation encapsulating albumin can be labeled with In-Oxine, and obtained stabilized formulation for long-term imaging, that have more favorable conditions for the evaluation of tumors and it will cause early diagnosis of tumors. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=nano%20liposome" title="nano liposome">nano liposome</a>, <a href="https://publications.waset.org/abstracts/search?q=111In-oxine" title=" 111In-oxine"> 111In-oxine</a>, <a href="https://publications.waset.org/abstracts/search?q=imaging" title=" imaging"> imaging</a>, <a href="https://publications.waset.org/abstracts/search?q=biodistribution" title=" biodistribution"> biodistribution</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor" title=" tumor"> tumor</a> </p> <a href="https://publications.waset.org/abstracts/162894/novel-liposomal-nanocarriers-for-long-term-tumor-imaging" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/162894.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">113</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">31</span> Absorbed Dose Estimation of 177Lu-DOTATOC in Adenocarcinoma Breast Cancer Bearing Mice</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri">S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Mousavi-Daramoroudi"> M. Mousavi-Daramoroudi</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia"> H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=F.%20Abbasi-Davani"> F. Abbasi-Davani </a> </p> <p class="card-text"><strong>Abstract:</strong></p> In this study, the absorbed dose of human organs after injection of <sup>177</sup>Lu-DOTATOC was studied based on the biodistribution of the complex in adenocarcinoma breast cancer bearing mice. For this purpose, the biodistribution of the radiolabelled complex was studied and compartmental modeling was applied to calculate the absorbed dose with high precision. As expected, <sup>177</sup>Lu-DOTATOC illustrated a notable specific uptake in tumor and pancreas, organs with high level of somatostatin receptor on their surface and the effectiveness of the radio-conjugate for targeting of the breast adenocarcinoma tumors was indicated. The elicited results of modeling were the exponential equations, and those are utilized for obtaining the cumulated activity data by taking their integral. The results also exemplified that non-target absorbed-doses such as the liver, spleen and pancreas were approximately 0.008, 0.004, and 0.039, respectively. While these values were so much lower than target (tumor) absorbed-dose, it seems due to this low toxicity, this complex is a good agent for therapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=%C2%B9%E2%81%B7%E2%81%B7Lu" title="¹⁷⁷Lu">¹⁷⁷Lu</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title=" breast cancer"> breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=compartmental%20modeling" title=" compartmental modeling"> compartmental modeling</a>, <a href="https://publications.waset.org/abstracts/search?q=dosimetry" title=" dosimetry"> dosimetry</a> </p> <a href="https://publications.waset.org/abstracts/97772/absorbed-dose-estimation-of-177lu-dotatoc-in-adenocarcinoma-breast-cancer-bearing-mice" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/97772.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">151</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">30</span> Compartmental Model Approach for Dosimetric Calculations of ¹⁷⁷Lu-DOTATOC in Adenocarcinoma Breast Cancer Based on Animal Data</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20S.%20Mousavi-Daramoroudi">M. S. Mousavi-Daramoroudi</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia"> H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri"> S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=F.%20Abbasi-Davani"> F. Abbasi-Davani</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Dosimetry is an indispensable and precious factor in patient treatment planning; to minimize the absorbed dose in vital tissues. In this study, In accordance with the proper characteristics of DOTATOC and ¹⁷⁷Lu, after preparing ¹⁷⁷Lu-DOTATOC at the optimal conditions for the first time in Iran, radionuclidic and radiochemical purity of the solution was investigated using an HPGe spectrometer and ITLC method, respectively. The biodistribution of the compound was assayed for treatment of adenocarcinoma breast cancer in bearing BALB/c mice. The results have demonstrated that ¹⁷⁷Lu-DOTATOC is a profitable selection for therapy of the tumors. Because of the vital role of internal dosimetry before and during therapy, the effort to improve the accuracy and rapidity of dosimetric calculations is necessary. For this reason, a new method was accomplished to calculate the absorbed dose through mixing between compartmental model, animal dosimetry and extrapolated data from animal to human and using MIRD method. Despite utilization of compartmental model based on the experimental data, it seems this approach may increase the accuracy of dosimetric data, confidently. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=%C2%B9%E2%81%B7%E2%81%B7Lu-DOTATOC" title="¹⁷⁷Lu-DOTATOC">¹⁷⁷Lu-DOTATOC</a>, <a href="https://publications.waset.org/abstracts/search?q=biodistribution%20modeling" title=" biodistribution modeling"> biodistribution modeling</a>, <a href="https://publications.waset.org/abstracts/search?q=compartmental%20model" title=" compartmental model"> compartmental model</a>, <a href="https://publications.waset.org/abstracts/search?q=internal%20dosimetry" title=" internal dosimetry"> internal dosimetry</a> </p> <a href="https://publications.waset.org/abstracts/74350/compartmental-model-approach-for-dosimetric-calculations-of-177lu-dotatoc-in-adenocarcinoma-breast-cancer-based-on-animal-data" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/74350.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">219</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">29</span> Ex-vivo Bio-distribution Studies of a Potential Lung Perfusion Agent</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Shabnam%20Sarwar">Shabnam Sarwar</a>, <a href="https://publications.waset.org/abstracts/search?q=Franck%20Lacoeuille"> Franck Lacoeuille</a>, <a href="https://publications.waset.org/abstracts/search?q=Nadia%20%20Withofs"> Nadia Withofs</a>, <a href="https://publications.waset.org/abstracts/search?q=Roland%20Hustinx"> Roland Hustinx</a> </p> <p class="card-text"><strong>Abstract:</strong></p> After the development of a potential surrogate of MAA, and its successful application for the diagnosis of pulmonary embolism in artificially embolized rats’ lungs, this microparticulate system were radiolabelled with gallium-68 to synthesize 68Ga-SBMP with high radiochemical purity >99%. As a prerequisite step of clinical trials, 68Ga- labelled starch based microparticles (SBMP) were analysed for their in-vivo behavior in small animals. The purpose of the presented work includes the ex-vivo biodistribution studies of 68Ga-SBMP in order to assess the activity uptake in target organs with respect to time, excretion pathways of the radiopharmaceutical, %ID/g in major organs, T/NT ratios, in-vivo stability of the radiotracer and subsequently the microparticles in the target organs. Radiolabelling of starch based microparticles was performed by incubating it with 68Ga generator eluate (430±26 MBq) at room temperature and pressure without using any harsh reaction condition. For Ex-vivo biodistribution studies healthy White Wistar rats weighing between 345-460 g were injected intravenously 68Ga-SBMP 20±8 MBq, containing about 2,00,000-6,00,000 SBMP particles in a volume of 700µL. The rats were euthanized at predefined time intervals (5min, 30min, 60min and 120min) and their organ parts were cut, washed, and put in the pre-weighed tubes and measured for radioactivity counts through automatic Gamma counter. The 68Ga-SBMP produced >99% RCP just after 10-20 min incubation through a simple and robust procedure. Biodistribution of 68Ga-SBMP showed that initially just after 5 min post injection major uptake was observed in the lungs following by blood, heart, liver, kidneys, bladder, urine, spleen, stomach, small intestine, colon, skin and skeleton, thymus and at last the smallest activity was found in brain. Radioactivity counts stayed stable in lungs with gradual decrease with the passage of time, and after 2h post injection, almost half of the activity were seen in lungs. This is a sufficient time to perform PET/CT lungs scanning in humans while activity in the liver, spleen, gut and urinary system decreased with time. The results showed that urinary system is the excretion pathways instead of hepatobiliary excretion. There was a high value of T/NT ratios which suggest fine tune images for PET/CT lung perfusion studies henceforth further pre-clinical studies and then clinical trials should be planned in order to utilize this potential lung perfusion agent. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=starch%20based%20microparticles" title="starch based microparticles">starch based microparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=gallium-68" title=" gallium-68"> gallium-68</a>, <a href="https://publications.waset.org/abstracts/search?q=biodistribution" title=" biodistribution"> biodistribution</a>, <a href="https://publications.waset.org/abstracts/search?q=target%20organs" title=" target organs"> target organs</a>, <a href="https://publications.waset.org/abstracts/search?q=excretion%20pathways" title=" excretion pathways"> excretion pathways</a> </p> <a href="https://publications.waset.org/abstracts/128551/ex-vivo-bio-distribution-studies-of-a-potential-lung-perfusion-agent" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/128551.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">173</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">28</span> PEG-b-poly(4-vinylbenzyl phosphonate) Coated Magnetic Iron Oxide Nanoparticles as Drug Carrier System: Biological and Physicochemical Characterization </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Magdalena%20Ha%C5%82upka-Bryl">Magdalena Hałupka-Bryl</a>, <a href="https://publications.waset.org/abstracts/search?q=Magdalena%20Bednarowicz"> Magdalena Bednarowicz</a>, <a href="https://publications.waset.org/abstracts/search?q=Ryszard%20Krzyminiewski"> Ryszard Krzyminiewski</a>, <a href="https://publications.waset.org/abstracts/search?q=Yukio%20Nagasaki"> Yukio Nagasaki </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Due to their unique physical properties, superparamagnetic iron oxide nanoparticles are increasingly used in medical applications. They are very useful carriers for delivering antitumor drugs in targeted cancer treatment. Magnetic nanoparticles (PEG-PIONs/DOX) with chemotherapeutic were synthesized by coprecipitation method followed by coating with biocompatible polymer PEG-derivative (poly(ethylene glycol)-block-poly(4-vinylbenzylphosphonate). Complete physicochemical characterization was carried out (ESR, HRTEM, X-ray diffraction, SQUID analysis) to evaluate the magnetic properties of obtained PEG-PIONs/DOX. Nanoparticles were investigated also in terms of their stability, drug loading efficiency, drug release and antiproliferative effect on cancer cells. PEG-PIONs/DOX have been successfully used for the efficient delivery of an anticancer drug into the tumor region. Fluorescent imaging showed the internalization of PEG-PIONs/DOX in the cytoplasm. Biodistribution studies demonstrated that PEG-PIONs/DOX preferentially accumulate in tumor region via the enhanced permeability and retention effect. The present findings show that synthesized nanosystem is promising tool for potential magnetic drug delivery. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=targeted%20drug%20delivery" title="targeted drug delivery">targeted drug delivery</a>, <a href="https://publications.waset.org/abstracts/search?q=magnetic%20properties" title=" magnetic properties"> magnetic properties</a>, <a href="https://publications.waset.org/abstracts/search?q=iron%20oxide%20nanoparticles" title=" iron oxide nanoparticles"> iron oxide nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=biodistribution" title=" biodistribution"> biodistribution</a> </p> <a href="https://publications.waset.org/abstracts/29050/peg-b-poly4-vinylbenzyl-phosphonate-coated-magnetic-iron-oxide-nanoparticles-as-drug-carrier-system-biological-and-physicochemical-characterization" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/29050.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">463</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">27</span> Preliminary dosimetric Evaluation of a New Therapeutic 177LU Complex for Human Based on Biodistribution Data in Rats</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia">H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri"> S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Golabi%20Dezfuli"> A. Golabi Dezfuli</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Tris (1,10-phenanthroline) lanthanum(III)] trithiocyanate is a new compound that has shown to stop DNA synthesis in CCRF-CEM and Ehrlich ascites cells leading to a cell cycle arrest in G0/G1. One other important property of the phenanthroline nucleus is its ability to act as a triplet-state photosensitizer especially in complexes with lanthanides. In Nowadays, the radiation dose assessment resource (RADAR) method is known as the most common method for absorbed dose calculation. 177Lu was produced by irradiation of a natural Lu2O3 target at a thermal neutron flux of approximately 4 × 1013 n/cm2•s. 177Lu-PL3 was prepared in the optimized condition. The radiochemical yield was checked by ITLC method. The biodistribution of the complex was investigated by intravenously injection to wild-type rats via their tail veins. In this study, the absorbed dose of 177Lu-PL3 to human organs was estimated by RADAR method. 177Lu was prepared with a specific activity of 2.6-3 GBq.mg-1 and radionuclide purity of 99.98 %. The 177Lu-PL3 complex can prepare with high radiochemical yield (> 99 %) at optimized conditions. The results show that liver and spleen have received the highest absorbed dose of 1.051 and 0.441 mSv/MBq, respectivley. The absorbed dose values for these two dose-limiting tissues suggest more biological studies special in tumor-bearing animals. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=internal%20dosimetry" title="internal dosimetry">internal dosimetry</a>, <a href="https://publications.waset.org/abstracts/search?q=Lutetium-177" title=" Lutetium-177"> Lutetium-177</a>, <a href="https://publications.waset.org/abstracts/search?q=radar" title=" radar"> radar</a>, <a href="https://publications.waset.org/abstracts/search?q=animals" title=" animals"> animals</a> </p> <a href="https://publications.waset.org/abstracts/34297/preliminary-dosimetric-evaluation-of-a-new-therapeutic-177lu-complex-for-human-based-on-biodistribution-data-in-rats" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/34297.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">372</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">26</span> Production, Quality Control, and Biodistribution Studies of 141ce-Edtmp as a Potential Bone Pain Palliation Agent</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Fatemeh%20Soltani">Fatemeh Soltani</a>, <a href="https://publications.waset.org/abstracts/search?q=Simindokht%20Shirvani%20Arani"> Simindokht Shirvani Arani</a>, <a href="https://publications.waset.org/abstracts/search?q=Ali%20Bahrami%20Samani"> Ali Bahrami Samani</a>, <a href="https://publications.waset.org/abstracts/search?q=Mahdi%20Sadeghi"> Mahdi Sadeghi</a>, <a href="https://publications.waset.org/abstracts/search?q=Kamal%20Yavari"> Kamal Yavari</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Cerium-141 [T1/2 = 32.501 days, Eβ (max) = 0.580 (29.8%) and 0.435(70.2%) MeV, Eγ=145.44 (48.2%) keV] possesses radionuclidic properties suitable for use in palliative therapy of bone metastases. 141Ce also has gamma energy of 145.44 keV, which resembles that of 99mTc. Therefore, the energy window is adjustable on the Tc-99m energy because of imaging studies. 141Ce can be produced through a relatively easy route that involves thermal neutron bombardment on natural CeO2 in medium flux research reactors (4–5×1013 neutrons/cm2•s). The requirement for an enriched target does not arise. Ethylenediamine tetramethylene phosphonic acid (EDTMP) was synthesized and radiolabeled with 141Ce. Complexation parameters were optimized to achieve maximum yields (>99%). The radiochemical purity of 141Ce-EDTMP was evaluated by radio-thin layer chromatography. The stability of the prepared formulation was monitored for one week at room temperature, and results showed that the preparation was stable during this period (>99%). Biodistribution studies of the complexes carried out in wild-type rats exhibited significant bone uptake with rapid clearance from blood. The properties of produced 141Ce-EDTMP suggest applying a new efficient bone pain palliative therapeutic agent to overcome metastatic bone pains. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=bone%20pain%20palliative" title="bone pain palliative">bone pain palliative</a>, <a href="https://publications.waset.org/abstracts/search?q=cerium-141" title=" cerium-141"> cerium-141</a>, <a href="https://publications.waset.org/abstracts/search?q=EDTMP" title=" EDTMP"> EDTMP</a>, <a href="https://publications.waset.org/abstracts/search?q=radiopharmaceutical" title=" radiopharmaceutical"> radiopharmaceutical</a> </p> <a href="https://publications.waset.org/abstracts/25113/production-quality-control-and-biodistribution-studies-of-141ce-edtmp-as-a-potential-bone-pain-palliation-agent" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/25113.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">489</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">25</span> Estimated Human Absorbed Dose of 111 In-BPAMD as a New Bone-Seeking Spect-Imaging Agent</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia">H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri"> S. Zolghadri</a> </p> <p class="card-text"><strong>Abstract:</strong></p> An early diagnosis of bone metastases is very important for providing a profound decision on a subsequent therapy. A prerequisite for the clinical application of new diagnostic radiopharmaceutical is the measurement of organ radiation exposure dose from biodistribution data in animals. In this study, the dosimetric studies of a novel agent for SPECT-imaging of bone methastases, 111In-(4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid (111In-BPAMD) complex, have been estimated in human organs based on mice data. The radiolabeled complex was prepared with high radiochemical purity at the optimal conditions. Biodistribution studies of the complex were investigated in male Syrian mice at selected times after injection (2, 4, 24 and 48 h). The human absorbed dose estimation of the complex was performed based on mice data by the radiation absorbed dose assessment resource (RADAR) method. 111In-BPAMD complex was prepared with high radiochemical purity >95% (ITLC) and specific activities of 2.85 TBq/mmol. Total body effective absorbed dose for 111In-BPAMD was 0.205 mSv/MBq. This value is comparable to the other 111In clinically used complexes. The results show that the dose to critical organs the complex is well within the acceptable considered range for diagnostic nuclear medicine procedures. Generally, 111In-BPAMD has interesting characteristics and can be considered as a viable agent for SPECT-imaging of the bone metastases in the near future. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=In-111" title="In-111">In-111</a>, <a href="https://publications.waset.org/abstracts/search?q=BPAMD" title=" BPAMD"> BPAMD</a>, <a href="https://publications.waset.org/abstracts/search?q=absorbed%20dose" title=" absorbed dose"> absorbed dose</a>, <a href="https://publications.waset.org/abstracts/search?q=RADAR" title=" RADAR"> RADAR</a> </p> <a href="https://publications.waset.org/abstracts/34599/estimated-human-absorbed-dose-of-111-in-bpamd-as-a-new-bone-seeking-spect-imaging-agent" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/34599.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">481</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">24</span> Biodistribution of Fluorescence-Labelled Epidermal Growth Factor Protein from Slow Release Nanozolid Depots in Mouse</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Stefan%20Gruden">Stefan Gruden</a>, <a href="https://publications.waset.org/abstracts/search?q=Charlott%20Brunmark"> Charlott Brunmark</a>, <a href="https://publications.waset.org/abstracts/search?q=Bo%20Holmqvist"> Bo Holmqvist</a>, <a href="https://publications.waset.org/abstracts/search?q=Erwin%20D.%20Brenndorfer"> Erwin D. Brenndorfer</a>, <a href="https://publications.waset.org/abstracts/search?q=Martin%20Johansson"> Martin Johansson</a>, <a href="https://publications.waset.org/abstracts/search?q=Jian%20Liu"> Jian Liu</a>, <a href="https://publications.waset.org/abstracts/search?q=Ying%20Zhao"> Ying Zhao</a>, <a href="https://publications.waset.org/abstracts/search?q=Niklas%20Axen"> Niklas Axen</a>, <a href="https://publications.waset.org/abstracts/search?q=Moustapha%20Hassan"> Moustapha Hassan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Aim: The study was designed to evaluate the ability of the calcium sulfate-based NanoZolid® drug delivery technology to locally release the epidermal growth factor (EGF) protein while maintaining its biological activity. Methods: NanoZolid-formulated EGF protein labelled with a near-infrared dye (EGF-NIR) depots or EGF-NIR dissolved in PBS were injected subcutaneously into mice bearing EGF receptor (EGFR) positive human A549 lung cancer tumors inoculated subcutaneously. The release and biodistribution of the EGF-NIR were investigated in vivo longitudinally up to 96 hours post-administration, utilizing whole-body fluorescence imaging. In order to confirm the in vivo findings, histological analysis of tumor cryosections was performed to investigate EGF-NIR fluorescent signal and EGFR expression level by immunofluorescence labelling. Results: The in vivo fluorescence imaging showed a controlled release profile of the EGF-NIR loaded in the NanoZolid depots compared to free EGF-NIR. Histological analysis of the tumors further demonstrated a prevailing distribution of EGF-NIR in regions with high levels of EGFR expression. Conclusion: Calcium sulfate based depots can be used to formulate EGF while maintaining its biological activity, e.g., receptor binding capability. This may have good clinical potential for local delivery of biomolecules to enhance treatment efficacy and minimize systemic adverse effects. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=bioresorbable" title="bioresorbable">bioresorbable</a>, <a href="https://publications.waset.org/abstracts/search?q=calcium%20sulfate" title=" calcium sulfate"> calcium sulfate</a>, <a href="https://publications.waset.org/abstracts/search?q=controlled%20release" title=" controlled release"> controlled release</a>, <a href="https://publications.waset.org/abstracts/search?q=NanoZolid" title=" NanoZolid"> NanoZolid</a> </p> <a href="https://publications.waset.org/abstracts/130796/biodistribution-of-fluorescence-labelled-epidermal-growth-factor-protein-from-slow-release-nanozolid-depots-in-mouse" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/130796.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">165</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">23</span> Hydrophobically Modified Glycol Chitosan Nanoparticles as a Carrier for Etoposide</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Akhtar%20Aman">Akhtar Aman</a>, <a href="https://publications.waset.org/abstracts/search?q=Abida%20Raza"> Abida Raza</a>, <a href="https://publications.waset.org/abstracts/search?q=Shumaila%20Bashir"> Shumaila Bashir</a>, <a href="https://publications.waset.org/abstracts/search?q=Javaid%20Irfan"> Javaid Irfan</a>, <a href="https://publications.waset.org/abstracts/search?q=Andreas%20G.%20Sch%C3%A4tzlein"> Andreas G. Schätzlein</a>, <a href="https://publications.waset.org/abstracts/search?q=Ijeoma%20F%20Uchegbeu"> Ijeoma F Uchegbeu</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Development of efficient delivery system for hydrophobic drugs remains a major concern in chemotherapy. The objective of the current study was to develop polymeric drug-delivery system for etoposide from amphiphilic derivatives of glycol chitosan, capable to improve the pharmacokinetics and to reduce the adverse effects of etoposide due to various organic solvents used in commercial formulations for solubilisation of etoposide. As a promising carrier, amphiphilic derivatives of glycol chitosan were synthesized by chemical grafting of palmitic acid N-hydroxy succinimide and quaternisation to glycol chitosan backbone. To this end a 7.9 kDa glycol chitosan was modified by palmitoylation and quaternisation into 13 kDa. Nano sized micelles prepared from this amphiphilic polymer had the capability to encapsulate up to 3 mg/ml etoposide. The pharmacokinetic results indicated that GCPQ based etoposide formulation transformed the biodistribution pattern. AUC 0.5-24 hr showed statistically significant difference in ETP-GCPQ vs. commercial preparation in liver (25 vs 70, p<0.001), spleen (27 vs. 36, P<0.05), lungs (42 vs. 136, p<0.001), kidneys (25 vs. 30, p<0.05) and brain (19 vs. 9,p<0.001). Using the hydrophobic fluorescent dye Nile red, we showed that micelles efficiently delivered their payload to MCF7 and A2780 cancer cells in-vitro and to A431 xenograft tumor in-vivo, suggesting these systems could deliver hydrophobic anti- cancer drugs such as etoposide to tumors. The pharmacokinetic results indicated that the GCPQ micelles transformed the biodistribution pattern and increased etoposide concentration in the brain significantly compared to free drug after intravenous administration. GCPQ based formulations not only reduced side effects associated with current available formulations but also increased their transport through the biological barriers, thus making it a good delivery system. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=glycol%20chitosan" title="glycol chitosan">glycol chitosan</a>, <a href="https://publications.waset.org/abstracts/search?q=Nile%20red" title=" Nile red"> Nile red</a>, <a href="https://publications.waset.org/abstracts/search?q=micelles" title=" micelles"> micelles</a>, <a href="https://publications.waset.org/abstracts/search?q=etoposide" title=" etoposide"> etoposide</a>, <a href="https://publications.waset.org/abstracts/search?q=A431%20xenografts" title=" A431 xenografts"> A431 xenografts</a> </p> <a href="https://publications.waset.org/abstracts/15339/hydrophobically-modified-glycol-chitosan-nanoparticles-as-a-carrier-for-etoposide" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/15339.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">310</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">22</span> Development of Positron Emission Tomography (PET) Tracers for the in-Vivo Imaging of α-Synuclein Aggregates in α-Synucleinopathies</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Bright%20Chukwunwike%20Uzuegbunam">Bright Chukwunwike Uzuegbunam</a>, <a href="https://publications.waset.org/abstracts/search?q=Wojciech%20%20Paslawski"> Wojciech Paslawski</a>, <a href="https://publications.waset.org/abstracts/search?q=Hans%20Agren"> Hans Agren</a>, <a href="https://publications.waset.org/abstracts/search?q=Christer%20Halldin"> Christer Halldin</a>, <a href="https://publications.waset.org/abstracts/search?q=Wolfgang%20Weber"> Wolfgang Weber</a>, <a href="https://publications.waset.org/abstracts/search?q=Markus%20Luster"> Markus Luster</a>, <a href="https://publications.waset.org/abstracts/search?q=Thomas%20Arzberger"> Thomas Arzberger</a>, <a href="https://publications.waset.org/abstracts/search?q=Behrooz%20Hooshyar%20Yousefi"> Behrooz Hooshyar Yousefi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> There is a need to develop a PET tracer that will enable to diagnosis and track the progression of Alpha-synucleinopathies (Parkinson’s disease [PD], dementia with Lewy bodies [DLB], multiple system atrophy [MSA]) in living subjects over time. Alpha-synuclein aggregates (a-syn), which are present in all the stages of disease progression, for instance, in PD, are a suitable target for in vivo PET imaging. For this reason, we have developed some promising a-syn tracers based on a disarylbisthiazole (DABTA) scaffold. The precursors are synthesized via a modified Hantzsch thiazole synthesis. The precursors were then radiolabeled via one- or two-step radiofluorination methods. The ligands were initially screened using a combination of molecular dynamics and quantum/molecular mechanics approaches in order to calculate the binding affinity to a-syn (in silico binding experiments). Experimental in vitro binding assays were also performed. The ligands were further screened in other experiments such as log D, in vitro plasma protein binding & plasma stability, biodistribution & brain metabolite analyses in healthy mice. Radiochemical yields were up to 30% - 72% in some cases. Molecular docking revealed possible binding sites in a-syn and also the free energy of binding to those sites (-28.9 - -66.9 kcal/mol), which correlated to the high binding affinity of the DABTAs to a-syn (Ki as low as 0.5 nM) and selectivity (> 100-fold) over Aβ and tau, which usually co-exist with a-synin some pathologies. The log D values range from 2.88 - 2.34, which correlated with free-protein fraction of 0.28% - 0.5%. Biodistribution experiments revealed that the tracers are taken up (5.6 %ID/g - 7.3 %ID/g) in the brain at 5 min (post-injection) p.i., and cleared out (values as low as 0.39 %ID/g were obtained at 120 min p.i. Analyses of the mice brain 20 min p.i. Revealed almost no radiometabolites in the brain in most cases. It can be concluded that in silico study presents a new venue for the rational development of radioligands with suitable features. The results obtained so far are promising and encourage us to further validate the DABTAs in autoradiography, immunohistochemistry, and in vivo imaging in non-human primates and humans. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=alpha-synuclein%20aggregates" title="alpha-synuclein aggregates">alpha-synuclein aggregates</a>, <a href="https://publications.waset.org/abstracts/search?q=alpha-synucleinopathies" title=" alpha-synucleinopathies"> alpha-synucleinopathies</a>, <a href="https://publications.waset.org/abstracts/search?q=PET%20imaging" title=" PET imaging"> PET imaging</a>, <a href="https://publications.waset.org/abstracts/search?q=tracer%20development" title=" tracer development"> tracer development</a> </p> <a href="https://publications.waset.org/abstracts/138870/development-of-positron-emission-tomography-pet-tracers-for-the-in-vivo-imaging-of-a-synuclein-aggregates-in-a-synucleinopathies" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/138870.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">235</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">21</span> Developing a Systemic Monoclonal Antibody Therapy for the Treatment of Large Burn Injuries</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Alireza%20Hassanshahi">Alireza Hassanshahi</a>, <a href="https://publications.waset.org/abstracts/search?q=Xanthe%20Strudwick"> Xanthe Strudwick</a>, <a href="https://publications.waset.org/abstracts/search?q=Zlatko%20Kopecki"> Zlatko Kopecki</a>, <a href="https://publications.waset.org/abstracts/search?q=Allison%20J%20Cowin"> Allison J Cowin</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Studies have shown that Flightless (Flii) is elevated in human wounds, including burns, and reducing the level of Flii is a promising approach for improving wound repair and reducing scar formation. The most effective approach has been to neutralise Flii activity using localized, intradermal application of function blocking monoclonal antibodies. However, large surface area burns are difficult to treat by intradermal injection of therapeutics, so the aim of this study was to investigate if a systemic injection of a monoclonal antibody against Flii could improve healing in mice following burn injury. Flii neutralizing antibodies (FnAbs) were labelled with Alxa-Fluor-680 for biodistribution studies and the healing effects of systemically administered FnAbs to mice with burn injuries. A partial thickness, 7% (70mm2) total body surface area scald burn injury was created on the dorsal surface of mice (n=10/group), and 100µL of Alexa-Flour-680-labeled FnAbs were injected into the intraperitoneal cavity (IP) at time of injury. The burns were imaged on days 0, 1, 2, 3, 4, and 7 using IVIS Lumina S5 Imaging System, and healing was assessed macroscopically, histologically, and using immunohistochemistry. Fluorescent radiance efficiency measurements showed that IP injected Alexa-Fluor-680-FnAbs localized at the site of burn injury from day 1, remaining there for the whole 7-day study. The burns treated with FnAbs showed a reduction in macroscopic wound area and an increased rate of epithelialization compared to controls. Immunohistochemistry for NIMP-R14 showed a reduction in the inflammatory infiltrate, while CD31/VEGF staining showed improved angiogenesis post-systemic FnAb treatment. These results suggest that systemically administered FnAbs are active within the burn site and can improve healing outcomes. The clinical application of systemically injected Flii monoclonal antibodies could therefore be a potential approach for promoting the healing of large surface area burns immediately after injury. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=biodistribution" title="biodistribution">biodistribution</a>, <a href="https://publications.waset.org/abstracts/search?q=burn" title=" burn"> burn</a>, <a href="https://publications.waset.org/abstracts/search?q=flightless" title=" flightless"> flightless</a>, <a href="https://publications.waset.org/abstracts/search?q=systemic" title=" systemic"> systemic</a>, <a href="https://publications.waset.org/abstracts/search?q=fnAbs" title=" fnAbs"> fnAbs</a> </p> <a href="https://publications.waset.org/abstracts/154516/developing-a-systemic-monoclonal-antibody-therapy-for-the-treatment-of-large-burn-injuries" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/154516.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">172</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">20</span> Optimization and Evaluation of 177lu-Dotatoc as a Potential Agent for Peptide Receptor Radionuclide Therapy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia">H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=MS.%20Mousavi-Daramoroudi"> MS. Mousavi-Daramoroudi</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri"> S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=F.%20Abbasi-Davani"> F. Abbasi-Davani</a> </p> <p class="card-text"><strong>Abstract:</strong></p> High expression of somatostatin receptors on a wide range of human tumours makes them as potential targets for peptide receptor radionuclide tomography. A series of octreotide analogues were synthesized while [DOTA-DPhe1, Tyr3]octreotide (DOTATOC) indicated advantageous properties in tumour models. In this study, 177Lu-DOTATOC was prepared with the radiochemical purity of higher than 99% in 30 min at the optimized condition. Biological behavior of the complex was studied after intravenous injection into the Syrian rats. Major difference uptake was observed compared to 177LuCl3 solution especially in somatostatin receptor-positive tissues such as pancreas and adrenal. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Biodistribution" title="Biodistribution">Biodistribution</a>, <a href="https://publications.waset.org/abstracts/search?q=177Lu" title=" 177Lu"> 177Lu</a>, <a href="https://publications.waset.org/abstracts/search?q=Octreotide" title=" Octreotide"> Octreotide</a>, <a href="https://publications.waset.org/abstracts/search?q=Syrian%20rats" title=" Syrian rats"> Syrian rats</a> </p> <a href="https://publications.waset.org/abstracts/34294/optimization-and-evaluation-of-177lu-dotatoc-as-a-potential-agent-for-peptide-receptor-radionuclide-therapy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/34294.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">448</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">19</span> Polymer Nanocarrier for Rheumatoid Arthritis Therapy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Vijayakameswara%20Rao%20Neralla">Vijayakameswara Rao Neralla</a>, <a href="https://publications.waset.org/abstracts/search?q=Jueun%20Jeon"> Jueun Jeon</a>, <a href="https://publications.waset.org/abstracts/search?q=Jae%20Hyung%20Park"> Jae Hyung Park</a> </p> <p class="card-text"><strong>Abstract:</strong></p> To develop a potential nanocarrier for diagnosis and treatment of rheumatoid arthritis (RA), we prepared a hyaluronic acid (HA)-5β-cholanic acid (CA) conjugate with an acid-labile ketal linker. This conjugate could self-assemble in aqueous conditions to produce pH-responsive HA-CA nanoparticles as potential carriers of the anti-inflammatory drug methotrexate (MTX). MTX was rapidly released from nanoparticles under inflamed synovial tissue in RA. In vitro cytotoxicity data showed that pH-responsive HA-CA nanoparticles were non-toxic to RAW 264.7 cells. In vivo biodistribution results confirmed that, after their systemic administration, pH-responsive HA-CA nanoparticles selectively accumulated in the inflamed joints of collagen-induced arthritis mice. These results indicate that pH-responsive HA-CA nanoparticles represent a promising candidate as a drug carrier for RA therapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=rheumatoid%20arthritis" title="rheumatoid arthritis">rheumatoid arthritis</a>, <a href="https://publications.waset.org/abstracts/search?q=hyaluronic%20acid" title=" hyaluronic acid"> hyaluronic acid</a>, <a href="https://publications.waset.org/abstracts/search?q=nanocarrier" title=" nanocarrier"> nanocarrier</a>, <a href="https://publications.waset.org/abstracts/search?q=self-assembly" title=" self-assembly"> self-assembly</a>, <a href="https://publications.waset.org/abstracts/search?q=MTX" title=" MTX"> MTX</a> </p> <a href="https://publications.waset.org/abstracts/72528/polymer-nanocarrier-for-rheumatoid-arthritis-therapy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/72528.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">289</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">18</span> Production, Quality Control and Biodistribution Assessment of 166 Ho-BPAMD as a New Bone Seeking Agent</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia">H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=N.%20Amraee"> N. Amraee</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Hosntalab"> M. Hosntalab</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri"> S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Bahrami-Samani"> A. Bahrami-Samani</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The aim of this study was the preparation of a new agent for bone marrow ablation in patients with multiple myeloma. 166Ho was produced at Tehran research reactor via 165Ho(n,γ)166Ho reaction. Complexion of Ho‐166 with BPAMD was carried out by the addition of about 200µg of BPAMD in absolute water to 1 mci of 166HoCl3 and warming up the mixture 90 0C for 1 h. 166Ho-BPAMD was prepared successfully with radio chemical purity of 95% which was measured by ITLC method. The final solution was injected to wild-type mice and bio distribution was determined up to 48 h. SPECT images were acquired after 2 and 48 h post injection. Both the bio distribution studies and SPECT imaging indicated high bone uptake, while accumulation in other organs was approximately negligible. The results show that 166Ho-BPAMD has suitable characteristics and can be used as a new bone marrow ablative agent. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=bone%20marrow%20ablation" title="bone marrow ablation">bone marrow ablation</a>, <a href="https://publications.waset.org/abstracts/search?q=BPAMD" title=" BPAMD"> BPAMD</a>, <a href="https://publications.waset.org/abstracts/search?q=166Ho" title=" 166Ho"> 166Ho</a>, <a href="https://publications.waset.org/abstracts/search?q=SPECT" title=" SPECT"> SPECT</a> </p> <a href="https://publications.waset.org/abstracts/18893/production-quality-control-and-biodistribution-assessment-of-166-ho-bpamd-as-a-new-bone-seeking-agent" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/18893.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">506</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">17</span> Functionalized Nanoparticles for Biomedical Applications</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Temesgen%20Geremew">Temesgen Geremew</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Functionalized nanoparticles have emerged as a revolutionary class of materials with immense potential in various biomedical applications. These engineered nanoparticles possess unique properties tailored to interact with biological systems, offering unprecedented opportunities in drug delivery, imaging, diagnostics, and therapy. This research delves into the design, synthesis, and characterization of functionalized nanoparticles for targeted biomedical applications. The primary focus lies on developing nanoparticles with precisely controlled size, surface chemistry, and biocompatibility for specific medical purposes. The research will also explore the crucial interaction of these nanoparticles with biological systems, encompassing cellular uptake, biodistribution, and potential toxicity evaluation. The successful development of functionalized nanoparticles holds the promise to revolutionize various aspects of healthcare. This research aspires to contribute significantly to this advancement by providing valuable insights into the design and application of these versatile materials within the ever-evolving field of biomedicine. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=nanoparticles" title="nanoparticles">nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=biomedicals" title=" biomedicals"> biomedicals</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=biocompatibility" title=" biocompatibility"> biocompatibility</a> </p> <a href="https://publications.waset.org/abstracts/183266/functionalized-nanoparticles-for-biomedical-applications" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/183266.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">66</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">16</span> Preliminary Dosimetric Evaluation of Two New 153Sm Bone Pain Palliative Agents</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia">H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri"> S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=N.%20Amraee"> N. Amraee</a>, <a href="https://publications.waset.org/abstracts/search?q=Z.%20Naseri"> Z. Naseri</a>, <a href="https://publications.waset.org/abstracts/search?q=Ar.%20Jalilian"> Ar. Jalilian </a> </p> <p class="card-text"><strong>Abstract:</strong></p> The purpose of this study was to calculate the absorbed dose to each human organ for two new Sm-153 bone-seeking agents in order to evaluate their effectiveness in bone pain palliation therapy. In this work, the absorbed dose of 153Sm-TTHMP and 153Sm-PDTMP to each human organ was evaluated based on biodistribution studies in rats by radiation dose assessment resource (RADAR) method. The highest absorbed dose for 153Sm-TTHMP and 153Sm-PDTMP is observed in trabecular bone with 1.844 and 3.167 mGy/MBq, respectively. Bone/red marrow dose ratio, as the target/critical organ dose ratio, for 153Sm-PDTMP is greater than 153Sm-TTHMP and is compatible with 153Sm-EDTMP. The results showed that these bone-seeking agents, specially 153Sm-PDTMP, have considerable characteristics compared to the most clinically used bone pain palliative radiopharmaceutical, and therefore, can be good candidates for bone pain palliation in patients with bone metastasis; however, further biological studies in other mammals are still needed. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=internal%20dosimetry" title="internal dosimetry">internal dosimetry</a>, <a href="https://publications.waset.org/abstracts/search?q=PDTMP" title=" PDTMP"> PDTMP</a>, <a href="https://publications.waset.org/abstracts/search?q=153Sm" title=" 153Sm"> 153Sm</a>, <a href="https://publications.waset.org/abstracts/search?q=TTHMP" title=" TTHMP"> TTHMP</a> </p> <a href="https://publications.waset.org/abstracts/18061/preliminary-dosimetric-evaluation-of-two-new-153sm-bone-pain-palliative-agents" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/18061.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">548</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">15</span> Evaluation of Labelling Conditions, Quality Control, and Biodistribution Study of 99mTc- D-Aminolevulinic Acid (5-ALA)</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Kalimullah%20Khan">Kalimullah Khan</a>, <a href="https://publications.waset.org/abstracts/search?q=Samina%20Roohi"> Samina Roohi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20Rafi"> Mohammad Rafi</a>, <a href="https://publications.waset.org/abstracts/search?q=Rizwana%20Zahoor"> Rizwana Zahoor</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Labeling of 5-Aminolevulinic acid (5-ALA) with 99 mTc was achieved by using tin chloride dihydrate (Sncl2.2H2O) as reducing agent. Radiochemical purity and labeling efficiency was determined by Whattman paper No.3 and instant thin layer chromatographic strips impregnated with silica gel (ITLC/SG). Labeling efficiency was dependent on many parameters such as amount of ligand, reducing agent, pH, and incubation time. Therefore, optimum conditions for maximum labeling were selected. Stability of 99 mTc- 5-ALA was also checked in fresh human serum. Tissue bio-distribution of 99 mTc-5-ALA was evaluated in Spargue Dawley rats. 5-ALA was 98% labeled with 99 mTc under optimum conditions, i.e. 100µg of 5-ALA, pH: 4, 10µg of Sncl2.2H2O and 30 minutes incubation at room temperature. 99 mTc labelled 5- ALA remained stable for 24 hours in human serum. Bio-distribution study (%ID/gm) in rats revealed that maximum accumulation of 99 mTc-5-ALA was in liver, spleen, stomach and intestine after half hour, 4 hours, and 24 hours. Significant activity in bladder and urine indicated urinary mode of excretion. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=99mTc-ALA" title="99mTc-ALA">99mTc-ALA</a>, <a href="https://publications.waset.org/abstracts/search?q=aminolevulinic%20acid" title=" aminolevulinic acid"> aminolevulinic acid</a>, <a href="https://publications.waset.org/abstracts/search?q=quality%20control" title=" quality control"> quality control</a>, <a href="https://publications.waset.org/abstracts/search?q=radiopharmaceuticals" title=" radiopharmaceuticals"> radiopharmaceuticals</a> </p> <a href="https://publications.waset.org/abstracts/5834/evaluation-of-labelling-conditions-quality-control-and-biodistribution-study-of-99mtc-d-aminolevulinic-acid-5-ala" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/5834.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">384</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">14</span> Comparison of Different in vitro Models of the Blood-Brain Barrier for Study of Toxic Effects of Engineered Nanoparticles</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Samir%20Dekali">Samir Dekali</a>, <a href="https://publications.waset.org/abstracts/search?q=David%20Crouzier"> David Crouzier</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Due to their new physico-chemical properties engineered nanoparticles (ENPs) are increasingly employed in numerous industrial sectors (such as electronics, textile, aerospace, cosmetics, pharmaceuticals, food industry, etc). These new physico-chemical properties can also represent a threat for the human health. Consumers can notably be exposed involuntarily by different routes such as inhalation, ingestion or through the skin. Several studies recently reported a possible biodistribution of these ENPs on the blood-brain barrier (BBB). Consequently, there is a great need for developing BBB in vitro models representative of the in vivo situation and capable of rapidly and accurately assessing ENPs toxic effects and their potential translocation through this barrier. In this study, several in vitro models established with micro-endothelial brain cell lines of different origins (bEnd.3 mouse cell line or a new human cell line) co-cultivated or not with astrocytic cells (C6 rat or C8-B4 mouse cell lines) on Transwells® were compared using different endpoints: trans-endothelial resistance, permeability of the Lucifer yellow and protein junction labeling. Impact of NIST diesel exhaust particles on BBB cell viability is also discussed. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=nanoparticles" title="nanoparticles">nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=blood-brain%20barrier" title=" blood-brain barrier"> blood-brain barrier</a>, <a href="https://publications.waset.org/abstracts/search?q=diesel%20exhaust%20particles" title=" diesel exhaust particles"> diesel exhaust particles</a>, <a href="https://publications.waset.org/abstracts/search?q=toxicology" title=" toxicology"> toxicology</a> </p> <a href="https://publications.waset.org/abstracts/18338/comparison-of-different-in-vitro-models-of-the-blood-brain-barrier-for-study-of-toxic-effects-of-engineered-nanoparticles" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/18338.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">440</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=biodistribution&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=biodistribution&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>